Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
A Study of TAVO412 in Patients with Cancer (TAVO412)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
January 07, 2025
Lead Product(s) : TAVO-101
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of TAVO101 in Atopic Dermatitis Patients
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 19, 2023
Lead Product(s) : TAVO-101
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of TAVO412 in Patients with Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
September 21, 2022
Lead Product(s) : Tavaborole
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of TAVO103A in Healthy Volunteers
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 06, 2022
Lead Product(s) : Tavaborole
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TAVO101
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of TAVO101 in Healthy Volunteers
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 28, 2022
Lead Product(s) : TAVO101
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tavo111
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : YuanBio Venture Capital
Deal Size : $20.0 million
Deal Type : Series A Financing
Details : The two rounds of financing will be used to accelerate the CMC production and IND filings of three antibody drugs (Tavo111, Tavo103, and Tavo101) developed by the company based on its TavoPrecise antibody platform.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
March 22, 2021
Lead Product(s) : Tavo111
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : YuanBio Venture Capital
Deal Size : $20.0 million
Deal Type : Series A Financing
Lead Product(s) : YS-ON-001,Tavo-201,YS-ON-002
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Yisheng Biopharma
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The objective of the alliance is to co-develop a combination therapy of involving Yisheng's & Tavotek's lead assets YS-ON-001/002 and Tavo-201/203 for cancer treatment.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
June 01, 2020
Lead Product(s) : YS-ON-001,Tavo-201,YS-ON-002
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Yisheng Biopharma
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Undisclosed
Recipient : Genmab
Deal Size : Undisclosed
Deal Type : Agreement
Details : The objective of the agreement is to develop a novel first-in-class immune-modulator bispecific antibody for auto-immune and inflammatory-related conditions, using DuoBody® technology, proprietary platform of Genmab A/S of Denmark.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 25, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Undisclosed
Recipient : Genmab
Deal Size : Undisclosed
Deal Type : Agreement